Catalyst Capital Advisors’s Denali Therapeutics DNLI Stock Holding History

Catalyst Capital Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-232	Closed	-$5K	–	508
2018 Q1	$5K	Hold	232	–	–	﹤0.01%	400
2017 Q4	$4K	Buy	+232	New	+$4.17K	﹤0.01%	400

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Catalyst Capital Advisors's DNLI Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of Denali Therapeutics (DNLI) in Q2 2018, closing a stake of 232 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in DNLI in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 67 funds tracked by Wall St. Rank hold DNLI as of Q2 2018.

Catalyst Capital Advisors reported no remaining Denali Therapeutics position as of Q2 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 232 Denali Therapeutics shares in Q2 2018, an estimated $5K.
Catalyst Capital Advisors first reported a position in Denali Therapeutics in Q4 2017 and held it in 2 quarters.
Catalyst Capital Advisors's Denali Therapeutics position peaked at $5K in Q1 2018.
67 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.